Literature DB >> 18923721

Health care-associated Staphylococcus aureus pneumonia.

Duncan Webster1, Linda Chui, Gregory J Tyrrell, Thomas J Marrie.   

Abstract

INTRODUCTION: While Staphylococcus aureus is an uncommon but serious cause of traditional community-acquired pneumonia (CAP), it is a predominant cause of nosocomial pneumonia in addition to the unique clinical entity of health care-associated pneumonia (HCAP). A cohort of bacteremic S aureus pneumonia cases was reviewed to determine the role of HCAP among the cohort, and to assess for differences between CAP and HCAP. PATIENTS AND METHODS: Bacteremic S aureus pneumonia cases were identified from a prospective study of all patients diagnosed with CAP who presented to hospitals in Edmonton, Alberta, between November 2000 and November 2002. These cases were subsequently reviewed retrospectively. Demographic, clinical and microbiological data were obtained, and patients were classified as having CAP or HCAP. Relatedness of isolates was determined by pulsed-field gel electrophoresis analysis in conjunction with epidemiological information.
RESULTS: There were 28 cases of bacteremic S aureus pneumonia identified. Fifty-seven per cent were reclassified as having HCAP, and 43% remained classified as having CAP. The CAP cohort was significantly younger than the HCAP cohort (mean age 49.0+/-23.7 years versus 67.8+/-18.6 years; P=0.035) with higher rates of intravenous drug use (50% versus 0%; P=0.002). Long-term care facility residence (44%) was common in the HCAP cohort. The HCAP cohort presented with more severe illness, having a higher mean pneumonia severity index score (143.1+/-41.1 versus 98.2+/-54.6; P=0.028), and despite fewer embolic complications, there was a trend toward a significantly higher mortality rate (31% versus 0%; P=0.052). Two community-acquired isolates cultured in the setting of intravenous drug use were methicillin-resistant, and no isolates were positive for Panton-Valentine leukocidin. There was evidence of relatedness involving 44% of the HCAP isolates by pulsed-field gel electrophoresis analysis.
CONCLUSION: HCAP accounts for a significant number of cases that, when using traditional definitions, would be classified as CAP. Severity of illness and mortality was excessive within the HCAP group. There was evidence of relatedness and spread of common strains in the HCAP cohort. The present study supports recommendations for treatment guidelines directed toward the entity of HCAP and the empirical coverage of S aureus among certain high-risk groups.

Entities:  

Keywords:  Community-acquired pneumonia; Health care-associated pneumonia; Staphylococcus aureus

Year:  2007        PMID: 18923721      PMCID: PMC2533551          DOI: 10.1155/2007/136796

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  35 in total

1.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can Respir J       Date:  2000 Sep-Oct       Impact factor: 2.409

2.  Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis.

Authors:  M R Mulvey; L Chui; J Ismail; L Louie; C Murphy; N Chang; M Alfa
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Staphylococcal pneumonia; a review of 21 cases in adults.

Authors:  A M FISHER; R W TREVER; J A CURTIN; G SCHULTZE; D F MILLER
Journal:  N Engl J Med       Date:  1958-05-08       Impact factor: 91.245

4.  Health-care-associated pneumonia: a new therapeutic paradigm.

Authors:  Kumiko Hiramatsu; Michael S Niederman
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

Review 5.  Infections due to Staphylococcus aureus.

Authors:  D M Musher; S O McKenzie
Journal:  Medicine (Baltimore)       Date:  1977-09       Impact factor: 1.889

Review 6.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

7.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

Review 8.  Pulmonary infections in patients with cystic fibrosis.

Authors:  Sujatha Rajan; Lisa Saiman
Journal:  Semin Respir Infect       Date:  2002-03

9.  Pulmonary infection due to methicillin-resistant Staphylococcus aureus.

Authors:  M T Cafferkey; E Abrahamson; A Bloom; C T Keane
Journal:  Scand J Infect Dis       Date:  1988

10.  Hematogenous staphylococcal pneumonia secondary to soft tissue infection.

Authors:  S Naraqi; G McDonnell
Journal:  Chest       Date:  1981-02       Impact factor: 9.410

View more
  3 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 3.  Microbiology of healthcare-associated infections and the definition accuracy to predict infection by potentially drug resistant pathogens: a systematic review.

Authors:  Teresa Cardoso; Mónica Almeida; Jordi Carratalà; Irene Aragão; Altamiro Costa-Pereira; António E Sarmento; Luís Azevedo
Journal:  BMC Infect Dis       Date:  2015-12-11       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.